TW202330579A - 經工程改造TGF-β單體及使用方法 - Google Patents

經工程改造TGF-β單體及使用方法 Download PDF

Info

Publication number
TW202330579A
TW202330579A TW111138471A TW111138471A TW202330579A TW 202330579 A TW202330579 A TW 202330579A TW 111138471 A TW111138471 A TW 111138471A TW 111138471 A TW111138471 A TW 111138471A TW 202330579 A TW202330579 A TW 202330579A
Authority
TW
Taiwan
Prior art keywords
tgf
seq
amino acid
residue
monomer
Prior art date
Application number
TW111138471A
Other languages
English (en)
Chinese (zh)
Inventor
安德魯 Ｐ 欣克
克里斯汀 德波
格雷戈 Ｍ 戴爾葛夫
Original Assignee
高等教育聯邦系統 匹茲堡大學
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 高等教育聯邦系統 匹茲堡大學 filed Critical 高等教育聯邦系統 匹茲堡大學
Publication of TW202330579A publication Critical patent/TW202330579A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/495—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Immunology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
TW111138471A 2021-10-11 2022-10-11 經工程改造TGF-β單體及使用方法 TW202330579A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163254249P 2021-10-11 2021-10-11
US63/254,249 2021-10-11

Publications (1)

Publication Number Publication Date
TW202330579A true TW202330579A (zh) 2023-08-01

Family

ID=85988028

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111138471A TW202330579A (zh) 2021-10-11 2022-10-11 經工程改造TGF-β單體及使用方法

Country Status (9)

Country Link
US (1) US20240425559A1 (enExample)
EP (1) EP4416172A4 (enExample)
JP (1) JP2024537234A (enExample)
KR (1) KR20240082356A (enExample)
CN (1) CN118103390A (enExample)
AU (1) AU2022367394B2 (enExample)
CA (1) CA3232809A1 (enExample)
TW (1) TW202330579A (enExample)
WO (1) WO2023064747A1 (enExample)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW517059B (en) * 1994-07-25 2003-01-11 Ciba Geigy Ag New process for the production of biologically active protein
US11091523B2 (en) * 2016-11-18 2021-08-17 University of Pittsburgh—of the Commonwealth System of Higher Education Engineered TGF-β monomers and their use for inhibiting TGF-β signaling
JP2023539195A (ja) * 2020-08-27 2023-09-13 ユニバーシティ オブ ピッツバーグ － オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 組換えトランスフォーミング増殖因子（ｔｇｆ）－ベータ単量体をコードする腫瘍溶解性ウイルスおよびその使用

Also Published As

Publication number Publication date
AU2022367394B2 (en) 2026-03-19
KR20240082356A (ko) 2024-06-10
CN118103390A (zh) 2024-05-28
AU2022367394A1 (en) 2024-04-11
CA3232809A1 (en) 2023-04-20
JP2024537234A (ja) 2024-10-10
WO2023064747A1 (en) 2023-04-20
EP4416172A4 (en) 2025-12-17
US20240425559A1 (en) 2024-12-26
EP4416172A1 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
US9074009B2 (en) Stabilized MAML peptides and uses thereof
EP2350126B1 (en) Bispecific egfr/igfir binding molecules
EP2917244B1 (en) Aprotinin-derived polypeptide-antibody conjugates
KR20110004471A (ko) 항혈관신생 화합물
JP2017529059A5 (enExample)
JP6279788B2 (ja) 抗癌剤に起因する末梢性神経障害性疼痛の予防及び／又は治療剤
US20200147183A1 (en) Cyclic acetylcholinesterase c-terminal peptide in the treatment or prevention of cancer or metastasis
US20220023395A1 (en) Methods of treating or preventing cancer with an agent that depletes tregs and a checkpoint inhibitor
CN118076373A (zh) 用于联合疗法的包括生长分化因子-15变体和胰高血糖素样肽-1受体激动剂的组合物
TW202330579A (zh) 經工程改造TGF-β單體及使用方法
HK40109585A (zh) 工程化TGF- β单体及其使用方法
CN111511917A (zh) 肽结合物
JP7375163B2 (ja) Ｔｇｆ－ベータトラップ
EP2138508A1 (en) Met agonists
AU2014200485A1 (en) Stabilized maml peptides and uses thereof
EP4263582A1 (en) Improved cell-penetrating peptides and fusion proteins
CN117750968A (zh) 用于预防或治疗非酒精性脂肪性肝病或非酒精性脂肪性肝炎的包括生长分化因子-15变体的组合物
HK40044828A (en) Medication for alleviating symptoms of peripheral neuropathy caused by anticancer drug and/or suppressing onset of peripheral neuropathy